U.S. Markets closed

Puma Biotechnology, Inc. (PBYI)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
104.50-0.30 (-0.29%)
At close: 4:00PM EDT
People also watch
CLVSICPTKITETSROBLUE

Puma Biotechnology, Inc.

10880 Wilshire Boulevard
Suite 2150
Los Angeles, CA 90024
United States
424-248-6500
http://www.pumabiotechnology.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees183

Key Executives

NameTitlePayExercisedAge
Mr. Alan H. AuerbachFounder, Chairman, Chief Exec. Officer, Pres and Sec.1.26MN/A47
Mr. Charles R. EylerSr. VP of Fin. & Admin. and Treasurer605.52kN/A69
Dr. Richard P. Bryce MBChB, MRCGP, MFPMChief Medical & Scientific Officer634.62k158.54k60
Mr. Steven LoChief Commercial Officer719.97kN/A50
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Corporate Governance

Puma Biotechnology, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 2; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.